Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 6

1.

Activation of a camptothecin prodrug by specific carboxylesterases as predicted by quantitative structure-activity relationship and molecular docking studies.

Yoon KJ, Krull EJ, Morton CL, Bornmann WG, Lee RE, Potter PM, Danks MK.

Mol Cancer Ther. 2003 Nov;2(11):1171-81.

2.

A virus-directed enzyme prodrug therapy approach to purging neuroblastoma cells from hematopoietic cells using adenovirus encoding rabbit carboxylesterase and CPT-11.

Meck MM, Wierdl M, Wagner LM, Burger RA, Guichard SM, Krull EJ, Harris LC, Potter PM, Danks MK.

Cancer Res. 2001 Jul 1;61(13):5083-9.

3.

Use of a modified ornithine decarboxylase promoter to achieve efficient c-MYC- or N-MYC-regulated protein expression.

Iyengar RV, Pawlik CA, Krull EJ, Phelps DA, Burger RA, Harris LC, Potter PM, Danks MK.

Cancer Res. 2001 Apr 1;61(7):3045-52.

4.

Use of the ornithine decarboxylase promoter to achieve N-MYC-mediated overexpression of a rabbit carboxylesterase to sensitize neuroblastoma cells to CPT-11.

Pawlik CA, Iyengar RV, Krull EJ, Mason SE, Khanna R, Harris LC, Potter PM, Danks MK, Guichard SM.

Mol Ther. 2000 May;1(5 Pt 1):457-63.

5.

Comparison of activation of CPT-11 by rabbit and human carboxylesterases for use in enzyme/prodrug therapy.

Danks MK, Morton CL, Krull EJ, Cheshire PJ, Richmond LB, Naeve CW, Pawlik CA, Houghton PJ, Potter PM.

Clin Cancer Res. 1999 Apr;5(4):917-24.

6.

Conversion of the CPT-11 metabolite APC to SN-38 by rabbit liver carboxylesterase.

Guichard SM, Morton CL, Krull EJ, Stewart CF, Danks MK, Potter PM.

Clin Cancer Res. 1998 Dec;4(12):3089-94.

Supplemental Content

Loading ...
Support Center